Clinical trial
Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in…
NCT00048633 · QLT Inc., Industry · Completed
Key facts
| NCT number | NCT00048633 |
|---|---|
| Title | Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in Chemotherapy Resistant Advanced Breast Cancer |
| Lead sponsor | QLT Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | Chemotherapy |
| Enrollment | 30 |
| Start date | Nov 1, 2001 |
| Primary completion | Jun 1, 2003 |
| Completion | Jun 1, 2003 |
| First posted | Nov 6, 2002 |
| Last update posted | May 23, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: